| Not Yet Recruiting | A Study of AK-1286 in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2025-02-01 |
| Not Yet Recruiting | YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | 2024-11-30 |
| Not Yet Recruiting | A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell L Peripheral T Cell Lymphoma | Phase 2 / Phase 3 | 2024-09-10 |
| Not Yet Recruiting | A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma Indolent B-cell Lymphoma | Phase 4 | 2024-04-30 |
| Unknown | A Study of HY-0102 in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2023-12-18 |
| Recruiting | Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS Advanced Solid Tumors | Phase 1 | 2023-10-24 |
| Unknown | A Study of YL-17231 in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2023-09-28 |
| Not Yet Recruiting | A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor Advanced Solid Tumors | Phase 1 / Phase 2 | 2023-08-31 |
| Unknown | A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 / Phase 2 | 2022-09-24 |
| Unknown | A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor Advanced Solid Tumor | Phase 1 | 2022-06-30 |
| Unknown | YL-13027 in Patients With Advanced Solid Tumors Solid Tumor | Phase 1 | 2022-05-17 |
| Unknown | A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lympho Peripheral T/NK Cell Lymphoma (R/R PTCL) | Phase 2 | 2022-05-01 |
| Unknown | Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation Advanced Solid Tumor | Phase 1 / Phase 2 | 2022-01-30 |
| Unknown | A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation Advanced Solid Tumor | Phase 1 / Phase 2 | 2021-11-09 |
| Unknown | A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer Effectiveness，Safety，Thymic Cancer | — | 2021-08-01 |
| Unknown | A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma PTCL | Phase 2 | 2021-04-01 |
| Unknown | A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma Follicular Lymphoma | Phase 2 | 2020-12-30 |
| Unknown | YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical T Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | 2020-08-20 |
| Completed | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma | Phase 1 | 2020-06-15 |
| Unknown | A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Relapsed or Refractory Peripheral T-Cell Lymphoma | Phase 1 | 2020-03-30 |
| Unknown | A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2019-08-01 |
| Unknown | A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma Lymphoma, Follicular | Phase 2 | 2019-04-29 |
| Unknown | First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors Advanced Solid Tumors | Phase 1 | 2019-03-19 |
| Unknown | A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies B-cell Lymphoma Recurrent, B-cell Chronic Lymphocytic Leukemia | Phase 1 | 2017-12-25 |